Novel AI system diagnoses brain tumour in 2 minutes during surgery

Expert pathologists typically require around 30 minutes to diagnose brain tumours from tissue samples extracted during surgery. A novel method of combining advanced optical imaging with an artificial intelligence (AI) algorithm produces accurate, real-time intraoperative diagnosis of brain tumours in less than 150 seconds, a new study finds.

The system can perform rapid and accurate diagnoses of brain tumours in practically real time, while the patient is still on the operating table. The AI system made diagnoses that were more accurate than those made by human pathologists and in a fraction of the time. Excitingly, the new system could be used in settings where expert neurologists aren’t available, and it holds promise as a technique that could diagnose other forms of cancer as well.

During cancer surgery, it’s not uncommon for surgeons to extract tissue for lab analysis. These intraoperative biopsies allow for more accurate diagnoses and to help the medical team devise next steps, such as scheduling a subsequent surgery to remove the tumour.

According to the new study, around 1.1 million brain samples are biopsied in the United States each year by trained neuropathologists. This process is “time, resource, and labour intensive.”

Looking to streamline this process, New York University neuroscientist Daniel Orringer and his colleagues developed a diagnostic technique that combined a powerful new optical imaging technique, called stimulated Raman histology (SRH), with an artificially intelligent deep neural network. SRH uses scattered laser light to illuminate features not normally seen in standard imaging techniques. During surgery, images acquired through SRH are evaluated by the AI algorithm, which needs less than 150 seconds to make its assessment, compared to the 20 to 30 minutes required by human neuropathologists. The authors “demonstrated how combining SRH with deep learning can be employed to rapidly predict intraoperative brain tumour diagnosis,” according to the paper.

Fascinatingly, the AI is also capable of detecting features in the biopsies not visible to the human eye.

Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.

“As surgeons, we’re limited to acting on what we can see; this technology allows us to see what would otherwise be invisible, to improve speed and accuracy in the operating room, and reduce the risk of misdiagnosis,” Orringer, the senior author of the paper, said. “With this imaging technology, cancer operations are safer and more effective than ever before.”

To create the deep neural network, the scientists trained the system on 2.5 million images taken from 415 patients. By the end of the training, the AI could categorise tissue into any of 13 common forms of brain tumours, such as malignant glioma, lymphoma, metastatic tumours, diffuse astrocytoma, and meningioma.

A clinical trial involving 278 brain tumour and epilepsy patients and three different medical institutions was then set up to test the efficacy of the system. SRH images were evaluated by either human experts or the AI. Looking at the results, the AI correctly identified the tumour 94.6% of the time, while the human neuropathologists were accurate 93.9% of the time. Interestingly, the errors made by humans were different than the errors made by the AI. This is actually good news, because it suggests the nature of the AI’s mistakes can be accounted for and corrected in the future, resulting in an even more accurate system.

“SRH will revolutionise the field of neuropathology by improving decision-making during surgery and providing expert-level assessment in the hospitals where trained neuropathologists are not available,” said Matija Snuderl, a co-author of the study and an associate professor at NYU Grossman School of Medicine, in the press release.

Also, because many of the histologic features seen in brain tumours are seen in other forms of cancer, this system could eventually be used in other fields and surgeries, including dermatology, gynaecology, breast surgery, and head and neck surgery, according to the study.

Differentiate your organisation, build thought leadership and boost lead generation by reaching the Australian Pharma, MedTech and Biotech industry professionals. Health Industry Hub offers unique media solutions to vendors and suppliers servicing the industry. Contact us.